Walgreens Boots Alliance, Inc. operates as a pharmacy-led health and beauty retail company. It operates through three segments: Retail Pharmacy USA, Retail Pharmacy International, and Pharmaceutical Wholesale. The Retail Pharmacy USA segment sells prescription drugs and an assortment of retail products, including health, wellness, beauty, personal care, consumable, and general merchandise products through its retail drugstores. It also provides specialty pharmacy services and mail services. As of August 31, 2020, this segment operated 9,021 retail stores under the Walgreens and Duane Reade brands in the United States; and six specialty pharmacies. The Retail Pharmacy International segment sells prescription drugs; and health and wellness, beauty, personal care, and other consumer products through its pharmacy-led health and beauty stores and optical practices, as well as through boots.com and an integrated mobile application. This segment operated 4,428 retail stores under the Boots, Benavides, and Ahumada in the United Kingdom, Thailand, Norway, the Republic of Ireland, the Netherlands, Mexico, and Chile; and 550 optical practices, including 165 on a franchise basis. The Pharmaceutical Wholesale segment engages in the wholesale and distribution of specialty and generic pharmaceuticals, health and beauty products, and home healthcare supplies and equipment, as well as provides related services to pharmacies and other healthcare providers. This segment operates in the United Kingdom, Germany, France, Turkey, Spain, the Netherlands, Egypt, Norway, Romania, the Czech Republic, and Lithuania. Walgreens Boots Alliance, Inc. was founded in 1901 and is based in Deerfield, Illinois.
IPO Year:
Exchange: NASDAQ
Website: walgreensbootsalliance.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/28/2025 | $11.00 → $9.00 | Hold → Sell | Deutsche Bank |
| 2/26/2024 | $23.00 | Market Perform | Leerink Partners |
| 2/20/2024 | Hold → Reduce | HSBC Securities | |
| 1/3/2024 | $21.00 | Underweight | Barclays |
| 12/22/2023 | $27.00 | Hold | HSBC Securities |
| 10/23/2023 | $27.00 → $30.00 | Neutral → Overweight | JP Morgan |
| 7/3/2023 | $37.00 → $27.00 | Underweight | Morgan Stanley |
| 6/28/2023 | $46.00 → $34.00 | Buy → Hold | Deutsche Bank |
| 2/23/2023 | $45.00 | Buy | Loop Capital |
| 11/23/2022 | $39.00 | Underweight | Morgan Stanley |
Deutsche Bank downgraded Walgreens Boots Alliance from Hold to Sell and set a new price target of $9.00 from $11.00 previously
Leerink Partners initiated coverage of Walgreens Boots Alliance with a rating of Market Perform and set a new price target of $23.00
HSBC Securities downgraded Walgreens Boots Alliance from Hold to Reduce
Barclays initiated coverage of Walgreens Boots Alliance with a rating of Underweight and set a new price target of $21.00
HSBC Securities initiated coverage of Walgreens Boots Alliance with a rating of Hold and set a new price target of $27.00
JP Morgan upgraded Walgreens Boots Alliance from Neutral to Overweight and set a new price target of $30.00 from $27.00 previously
Morgan Stanley reiterated coverage of Walgreens Boots Alliance with a rating of Underweight and set a new price target of $27.00 from $37.00 previously
Deutsche Bank downgraded Walgreens Boots Alliance from Buy to Hold and set a new price target of $34.00 from $46.00 previously
Loop Capital initiated coverage of Walgreens Boots Alliance with a rating of Buy and set a new price target of $45.00
Morgan Stanley resumed coverage of Walgreens Boots Alliance with a rating of Underweight and set a new price target of $39.00